Early Detection is Key in Managing Lung Toxicity with TDXD

When TDXD first entered the market, there were concerns surrounding its potential for lung toxicity. Early trials reported a 2% to 3% mortality rate due to institutional lung disease, primarily pneumonitis. This sparked caution among medical professionals and patients alike.

A Shift Towards Prophylactic Monitoring

With advancements in monitoring techniques, the mortality rate associated with TDXD has now dropped to 0%. The key lies in early detection of pneumonitis. Waiting for a patient to experience symptoms like shortness of breath or low oxygen levels (grade 2 pneumonitis) is too late; the drug must be permanently discontinued at this stage.

Prophylactic CT Scans: A Game Changer

The solution involves prophylactic CT scans every 6 to 8 weeks. This allows for the identification of any pneumonitis changes before the patient becomes symptomatic. If any abnormalities are detected, the drug is held until resolution. Steroids are administered during this period.

Resuming Treatment with Vigilance

Once the pneumonitis resolves, treatment with TDXD can be resumed and monitored closely for another 6 to 8 weeks. This proactive approach has proven to be effective in mitigating the risk of severe lung toxicity associated with TDXD.

The Importance of Early Intervention

Early detection through prophylactic CT scans is crucial for managing potential side effects and ensuring that patients can continue benefiting from TDXD, a vital tool in treating HER2-positive advanced breast cancer. This approach allows for the safe and effective utilization of this powerful treatment option.